References
Altena, R., Perik, P.J., van Veldhuisen, D.J., de Vries, E.G.E., & Gietema, J.A. (2009). Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncology, 10(4), 391-399.
Carver, J.R., Shapiro, C.L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K.S., et al. (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: Cardiac and pulmonary late effects. Journal of Clinical Oncology, 25(25), 3991-4008.
Ganz, P.A., Hussey, M.A., Moinpour, C.M., Unger, J.M., Hutchins, L.F., Dakhil, S.R., et al. (2008). Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group Protocol S8897. Journal of Clinical Oncology, 26(8), 1223-1230.
Gianni, L., Baselga, J., Eiermann, W., Guillem Porta, V., Semiglazov, V., Lluch, A., et al. (2005). Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clinical Cancer Research, 11(24), 8715-8721.
Gianni, L., Salvatorelli, E., & Minotti, G. (2007). Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 7(2), 67-71.
Giordano, S.H., Kuo, Y.F., Freeman, J.L., Bucholz, T.A., Hortobagyi, G.N., & Goodwin, J.S. (2005). Risk of cardiac death after adjuvant radiotherapy for breast cancer. Journal of the National Cancer Institute, 97(6), 419-424.
Hall, J.K., & Hall, D. (2001). Elements of nursing negligence. In M.E. O'Keefe (Ed.), Nursing practice and the law: Avoiding malpractice and other legal risks (pp. 140-141). Philadelphia: F.A. Davis.
Hershman, D.L., & Shao, T. (2009). Anthracycline toxicity after breast cancer treatment. Oncology, 23(3), 227-239.
Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. (2005). ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 112(12), E154-E235.
Kaszyk, L.K. (1986). Cardiac toxicity associated with cancer therapy. Oncology Nursing Forum, 13(4), 81-88.
Loerzel, V.W., & Dow, K.H. (2003). Cardiac toxicity related to cancer treatment. Clinical Journal of Oncology Nursing, 7(5), 557-562.
Mitani, I., Jain, D., Joska, T.M., Burtness, B., & Zaret, B.L. (2003). Doxorubicin cardiotoxicity: Prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era. Journal of Nuclear Cardiology, 10(2), 132-139.
Rosenthal, D.S., & Braunwald, E. (2001). Cardiac effects of radiation therapy and chemotherapy. In E. Braunwald (Ed.), Heart disease: A textbook of cardiovascular medicine (pp. 1746-1751). Philadelphia: W.B. Saunders.
Sabel, M.S., Levine, E.G., Hurd, T., Schwartz, G.N., Zielinski, R., Hohn, D., et al. (2001). Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy? American Journal of Clinical Oncology, 24(4), 425-428.
Safra, T. (2007). Chemotherapeutics and cardiac toxicity: Treatment considerations and management strategies. Community Oncology, 4(9), 540-548.
Shan, K., Lincoff, M., & Young, J.B. (1996). Anthracycline-induced cardiotoxicity. Annals of Internal Medicine, 125(1), 47-58.
Shelton, B.K. (2009). Cardiovascular toxicity. In M. Polovich, J.M. Whitford, & M. Olsen (Eds.), Chemotherapy and biotherapy guidelines and recommendations for practice. (3rd ed.). Pittsburgh, PA: Oncology Nursing Society.
Teytelman, Y. (2002). Effective nursing documentation and communication. Seminars in Oncology Nursing, 18(2), 121-127.
Von Hoff, D.D., Layard, M.W., Basa, P., Davis, J.L., Von Hoff, A.L., Rosenzweig, M., et al. (1979). Risk factors for doxorubicininduced congestive heart failure. Annals of Internal Medicine, 91(5), 710-717.
Youssef, G., & Links, M. (2005). The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. American Journal of Cardiovascular Drugs, 5(4), 233-243.
Altena, R., Perik, P.J., van Veldhuisen, D.J., de Vries, E.G.E., & Gietema, J.A. (2009). Cardiovascular toxicity caused by cancer treatment: Strategies for early detection. Lancet Oncology, 10(4), 391-399.
Ganz, P.A., Hussey, M.A., Moinpour, C.M., Unger, J.M., Hutchins, L.F., Dakhil, S.R., et al. (2008). Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group Protocol S8897. Journal of Clinical Oncology, 26(8), 1223-1230.
Gianni, L., Salvatorelli, E., & Minotti, G. (2007). Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes. Cardiovascular Toxicology, 7(2), 67-71.
Hall, J.K., & Hall, D. (2001). Elements of nursing negligence. In M.E. O'Keefe (Ed.), Nursing practice and the law: Avoiding malpractice and other legal risks (pp. 140-141). Philadelphia: F.A. Davis.
Hershman, D.L., & Shao, T. (2009). Anthracycline toxicity after breast cancer treatment. Oncology, 23(3), 227-239.
Hunt, S.A., Abraham, W.T., Chin, M.H., Feldman, A.M., Francis, G.S., Ganiats, T.G., et al. (2005). ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 112(12), E154-E235.
Rosenthal, D.S., & Braunwald, E. (2001). Cardiac effects of radiation therapy and chemotherapy. In E. Braunwald (Ed.), Heart disease: A textbook of cardiovascular medicine (pp. 1746-1751). Philadelphia: W.B. Saunders.
Safra, T. (2007). Chemotherapeutics and cardiac toxicity: Treatment considerations and management strategies. Community Oncology, 4(9), 540-548.
Shan, K., Lincoff, M., & Young, J.B. (1996). Anthracycline-induced cardiotoxicity. Annals of Internal Medicine, 125(1), 47-58.
Youssef, G., & Links, M. (2005). The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. American Journal of Cardiovascular Drugs, 5(4), 233-243.